Sharply increased mass loss from glaciers and ice caps in the Canadian Arctic Archipelago

Mountain glaciers and ice caps are contributing significantly to present rates of sea level rise and will continue to do so over the next century and beyond. The Canadian Arctic Archipelago, located off the northwestern shore of Greenland, contains one-third of the global volume of land ice outside the ice sheets, but its contribution to sea-level change remains largely unknown. Here we show that the Canadian Arctic Archipelago has recently lost 61?±?7?gigatonnes per year (Gt?yr(-1)) of ice, contributing 0.17?±?0.02 mm?yr(-1) to sea-level rise. Our estimates are of regional mass changes for the ice caps and glaciers of the Canadian Arctic Archipelago referring to the years 2004 to 2009 and are based on three independent approaches: surface mass-budget modelling plus an estimate of ice discharge (SMB+D), repeat satellite laser altimetry (ICESat) and repeat satellite gravimetry (GRACE). All three approaches show consistent and large mass-loss estimates. Between the periods 2004-2006 and 2007-2009, the rate of mass loss sharply increased from 31?±?8?Gt?yr(-1) to 92?±?12?Gt?yr(-1) in direct response to warmer summer temperatures, to which rates of ice loss are highly sensitive (64?±?14?Gt?yr(-1) per 1?K increase). The duration of the study is too short to establish a long-term trend, but for 2007-2009, the increase in the rate of mass loss makes the Canadian Arctic Archipelago the single largest contributor to eustatic sea-level rise outside Greenland and Antarctica.     

Home range and activity patterns of black-tailed jackrabbits

Home range use and activity patterns of black-tailed jackrabbits ( Lepus californicus ) in northern Utah were studied using telemetry. Home range sizes ranged from 2 to 3 km 2 and did not differ between sexes or among seasons. Jackrabbits were inactive during daylight, became active at dusk, and remained active throughout the night. Animals often traversed their home ranges in a few hours. During the breeding season, males were more active than females. Jackrabbits were most active during well-lit nights, and high winds decreased jackrabbit activity.     

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

Accumulation of amyloid fibrils in the viscera and connective tissues causes systemic amyloidosis, which is responsible for about one in a thousand deaths in developed countries. Localized amyloid can also have serious consequences; for example, cerebral amyloid angiopathy is an important cause of haemorrhagic stroke. The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present. There is therefore a major unmet need for therapy that safely promotes the clearance of established amyloid deposits. Over 20 different amyloid fibril proteins are responsible for different forms of clinically significant amyloidosis and treatments that substantially reduce the abundance of the respective amyloid fibril precursor proteins can arrest amyloid accumulation. Unfortunately, control of fibril-protein production is not possible in some forms of amyloidosis and in others it is often slow and hazardous. There is no therapy that directly targets amyloid deposits for enhanced clearance. However, all amyloid deposits contain the normal, non-fibrillar plasma glycoprotein, serum amyloid P component (SAP). Here we show that administration of anti-human-SAP antibodies to mice with amyloid deposits containing human SAP triggers a potent, complement-dependent, macrophage-derived giant cell reaction that swiftly removes massive visceral amyloid deposits without adverse effects. Anti-SAP-antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-d-proline compound CPHPC, thereby enabling injected anti-SAP antibodies to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.